On Monday, Shares of Texas Instruments Incorporated (NASDAQ:TXN), gained 1.33% to $56.88.
Texas Instruments, declared MSP430 FRAM microcontrollers (MCUs) with CapTIvate™ technology, the world’s lowest-power capacitive touch MCUs. The new MSP430FR2633 MCU with CapTIvate technology offers comprehensive hardware and software features for the most reliable performance in noise-challenged applications, counting electronic access controls, appliances, personal electronics, industrial control panels and more. Expanding TI’s 16-bit ultra-low-power FRAM MCU portfolio, the MSP430FR2633 MCU with CapTIvate technology enables designers of all skill levels to build robust human-machine interfaces (HMI) with capacitive buttons, sliders, wheels or proximity (BSWP) sensors. It also enables multi-touch designs with plastic, glass and metal overlays of various thicknesses. Designers can quickly create innovative solutions with the new CapTIvate Design Center, a graphical user interface (GUI) that allows developers to drag and drop sensors for quick system configuration and start tuning for performance in five minutes or less.
Experience the difference in low power with FRAM and CapTIvate technology.
Wake-on-touch hardware on chip can continuously scan up to four electrodes while the CPU is shut down, enabling up to 15 years of operation on a single coin cell battery with industry-leading current consumption of 0.9µA per button in sleep mode. The industry’s broadest portfolio of ultra-low-power MCUs with Ferroelectric Random Access Memory (FRAM) feature non-volatile memory with greater endurance and 100 times faster write speeds, enabling systems to wake from the lowest power standby modes in a fraction of the time. FRAM also provides the option of saving and restoring button state in the event of power failure without the use of space-consuming backup batteries.
MSP430FR2633 MCUs with CapTIvate technology offer developers a great deal of design flexibility without compromises. In an access control system, a proximity sensor may be needed to illuminate the screen and a large matrix of buttons to support user input. Self-capacitance provides higher sensitivity for proximity sensing, while mutual-capacitance allows for a large number of tightly packed buttons with lower crosstalk. CapTIvate technology provides flexibility to simultaneously support self-capacitance and mutual capacitance for an improved system solution. The MSP430FR2633 MCU can support 16 button self-capacitance and 64 button mutual-capacitance modes.
TI’s new CapTIvate technology, offered for the first time on the MSP430FR2633 MCU, provides advanced hardware features like a dedicated voltage regulator, frequency hopping, zero crossing synchronization and signal processing algorithms that prevent false detects in noisy environments. Furthermore, spread spectrum clocking lowers electromagnetic radiation, reducing emissions to system circuitry.
Texas Instruments Incorporated designs, manufactures, and sells semiconductors to electronics designers and manufacturers worldwide. It operates through two segments, Analog and Embedded Processing.
Shares of Opko Health Inc. (NYSE:OPK), declined -0.79% to $10.64, during its last trading session.
Cocrystal Pharma, declared the filing of its quarterly financial statements (10-Q) and offered an update on several of its antiviral programs.
2015 THIRD QUARTER FINANCIAL RESULTS
Research and Development (R&D) expense during the third quarter was $2.18 million contrast to $0.87 million for the same period in 2014. The $1.3 million improvement was due to expenses related to the November 2014 merger between Cocrystal Pharma and RFS Pharma and higher costs to support pre-clinical development activities.
During the third quarter of 2015, Selling, General and Administrative (SG&A) expense was $1.4 million contrast to $0.4 million for the same period in 2014. The $1.0 million improvement was due to compensation related costs, mostly stock options, and professional service costs primarily related to being a public company. At the end of third quarter, the company’s cash balance was $12.4 million.
“We continue to expand our discovery, pre-clinical and clinical capabilities focusing on bringing our broad-spectrum of antiviral drug candidates into the clinic,” stated CEO, Jeffrey Meckler. “With the addition of key hires, such as the recent recruitment of Dr. Douglas Mayers as our Chief Medical Officer, we are transforming Cocrystal into a clinical development company. We also look forward to expanding our expertise in critical areas to develop more programs in areas of unmet medical needs.”
OPKO Health, Inc., a biopharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies in the United States and internationally. It operates through two segments, Pharmaceuticals and Diagnostics.
Finally, Shares of Met life Inc (NYSE:MET), ended its last trade with 1.16% gain, and closed at $50.47.
MetLife, declared that it has declared a quarterly dividend of $0.25277777 per share on the company’s floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE: METPrA). The company also declared an initial dividend of $28.29166666 per share on the company’s 5.250% fixed-to-floating rate non-cumulative preferred stock, Series C, with a liquidation preference of $1,000 per share. Both dividends will be payable Dec. 15, 2015, to shareholders of record as of Nov. 30, 2015.
MetLife, Inc. provides life insurance, annuities, employee benefits, and asset administration products in the United States, Japan, Latin America, Asia, Europe, and the Middle East. It operates in six segments: Retail; Group, Voluntary & Worksite Benefits; Corporate Benefit Funding; Latin America; Asia; and Europe, the Middle East and Africa.